Nektar Therapeutics
NKTR
239 hedge funds and large institutions have $2.5B invested in Nektar Therapeutics in 2026 Q2 according to their latest regulatory filings, with 70 funds opening new positions, 102 increasing their positions, 42 reducing their positions, and 45 closing their positions.
143% more repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 42
65% more call options, than puts
Call options by funds: $117M | Put options by funds: $70.8M
56% more first-time investments, than exits
New positions opened: 70 | Existing positions closed: 45
29% more capital invested
Capital invested by funds: $1.94B → $2.5B (+$567M)
12.26% more ownership
Funds ownership: 93.9% → 106.16% (+12%)
11% more funds holding
Funds holding: 216 → 239 (+23)
29% less funds holding in top 10
Funds holding in top 10: 14 → 10 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$165M |
| 2 |
TSC
Two Seas Capital
Rye,
New York
|
+$82.9M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$56M |
| 4 |
VPC
Vestal Point Capital
New York
|
+$52.3M |
| 5 |
State Street
Boston,
Massachusetts
|
+$48.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$35.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$25.9M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$19M |
| 4 |
DI
Deeter Investments
Austin,
Texas
|
-$17.2M |
| 5 |
JP Morgan Chase
New York
|
-$15.9M |
NKTR Hedge Fund Activity: Q2 2026 in Review
239 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in Nektar Therapeutics (NKTR) for Q2 2026, worth a combined $2.5B — up 29% from $1.94B a quarter earlier.
Buyers outnumbered sellers: 70 funds opened new NKTR positions and 45 closed out — a net gain of 25 holders — while 102 added to existing stakes and 42 trimmed.
The largest buyer was BlackRock, adding an estimated $165M. The largest seller was Invesco, cutting an estimated $35.7M.
- 239 institutional investors held Nektar Therapeutics (NKTR) as of Q2 2026, up from 216 in Q1 2026.
- Funds reported $2.5B of Nektar Therapeutics stock for Q2 2026, up 29% quarter-over-quarter.
- 70 funds opened new Nektar Therapeutics positions in Q2 2026 and 45 closed out, a net change of +25 holders.
- The largest Nektar Therapeutics buyer in Q2 2026 was BlackRock, an estimated $165M added.
- The largest Nektar Therapeutics seller in Q2 2026 was Invesco, an estimated $35.7M sold.
Based on aggregated 13F filings for Q2 2026.